It could actually be an additional regulatory de novo mutation or epigenetic mutation that is preventing the expression of that mutated gene. Despite what peop

It could actually be an additional regulatory de novo mutation or epigenetic mutation that is preventing the expression of that mutated gene. Despite what people below say, understanding the pathways involved is significant because drugs can be made to replicate the same biological effect to block the disease. This is what biopharma looks for.